J&J beats lawsuit alleging Tylenol defect; Valeant has made billions for others than Ackman;

@FiercePharma: India pharma sees trouble for its industry in newly negotiated TPP. More | Follow @FiercePharma

@EricPFierce: Pests, lack of data integrity thwart another Indian API maker, this time Unimark Remedies. News | Follow @EricPFierce

@CarlyHFierce: After FDA snub, AZ diabetes combo faces potential years-long delay. Article | Follow @CarlyHFierce

> Johnson & Johnson ($JNJ) has won the first lawsuit to go to trial alleging its Extra Strength Tylenol was defectively designed. Story

> Ackman is not the only hedge fund operator who has made billions of dollars from shares in Valeant Pharmaceuticals. Forbes post

> The global market for treating peripheral artery disease (PAD) is expected to peak at nearly in 2020 before falling off as generics undercut sales of Brilinta and Xarelto. Story

> A state judge has ruled that Arizona's law restricting the use of morning after pills violates the state's constitution. Story

Medical Device News

@FierceMedDev: Check out this year's Fierce 15: The new strategic med tech mania sets the stage for 2015's Fierce 15. Feature | Follow @FierceMedDev

@VarunSaxena2: #TCT15: Startup's minimally invasive mitral valve repair tech shows promise in feasibility study. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: 23andMe adds chapter to comeback story with $115M in funding. Report | Follow @EmilyWFierce

> Theranos dials down lab testing amid FDA pushback. Story

> WSJ: Former Theranos employees reveal problems with proprietary testing device. More

Biotech News

@FierceBiotech: FierceBiotech Radio on Lilly's latest pipeline peril, Mylan's M&A broken record, and German Merck's big rebrand. More | Follow @FierceBiotech

@JohnCFierce: Zafgen hammered (again) as FDA clamps partial hold on PhIII obesity drug. Report | Follow @JohnCFierce

@DamianFierce: Lost in all this is that "Theranos" would have been a great name for a black metal band. | Follow @DamianFierce

> Biotech notches another $2B VC quarter, but can it last? More

> PTC's muscular dystrophy drug fails another key test with approval on the line. Article